RARECast: Programming the Immune System to Produce Drugs
May 11, 2015
MPS I is a rare genetic disease that is incurable and lethal by age 12. Seattle-base Immusoft thinks it can harness a key part of the immune system to manufacture a missing enzyme needed to treat the disease. It represents a broader effort on the part of the company to develop a platform to treat a wide range of disease by turning immune system cells into drug factories. We spoke to Matthew Scholz, CEO of Immusoft, about the company’s work, the process for programming these cells, and how the inspiration for its approach came from the computer industry.
RARECast is a weekly series by Daniel S. Levine. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Read his full bio here.
Sign up for updates straight to your inbox.